Opko Health announced this week that it has obtained the exclusive worldwide rights from Taiwan's Academia Sinica to a novel technology to develop protein vaccines against influenza and other viral infections.
Terms of the licensing deal were not disclosed.
Opko said that it is forming a Taiwanese subsidiary to collaborate with Academia Sinica in developing the first product from the technology platform, a universal flu vaccine.
The arrangement marks the latest step away from the RNAi field for Opko, which bills itself primarily as an ophthalmics firm. As reported by RNAi News last month, the company has conducted a number of business transactions over 2009, including investments in antibody and small-molecule drug developers, raising questions about its commitment to the gene-silencing technology (see RNAi News, 6/25/2009).